Towards a quality assurance for dosimetry in peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE

被引：0
|
作者：
Marin, G. [1 ]
Vanderlinden, B. [1 ]
Wimana, Z. [1 ]
Guiot, T. [1 ]
Karfis, I. [1 ]
Flamen, P. [1 ]
机构：
[1] Inst Jules Bordet, B-1000 Brussels, Belgium
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2015年 / 42卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
OP386
引用
收藏
页码：S159 / S160
页数：2
相关论文
共 50 条
  • [1] Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-DOTATATE; dosimetric findings
    Mok, S.
    Tay, Y.
    Ng, D.
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2014, 41 : S532 - S532
  • [2] Biphasic exponential dosimetry model for 177Lu-DOTATATE peptide receptor radionuclide therapy
    Chen, Sirong
    Cheng, Kam
    Li, Ka Chun
    Leung, Yim Lung
    Cheung, William
    Wong, Ka Nin
    Wong, Yuet Hung
    Ho, Chi-Lai
    [J]. JOURNAL OF NUCLEAR MEDICINE, 2018, 59
  • [3] Establishing a clinical dosimetry protocol for 177Lu-DOTATATE peptide receptor radionuclide therapy
    Bissell, S.
    Ross, E.
    McMeekin, H.
    Seal, E.
    Ogunwale, K.
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2020, 47 (SUPPL 1) : S106 - S106
  • [4] Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-DOTATATE in Individuals with Neck or Mediastinal Paraganglioma (PGL)
    Zovato, S.
    Kumanova, A.
    Dematte, S.
    Sansovini, M.
    Bodei, L.
    Di Sarra, D.
    Casagranda, E.
    Severi, S.
    Ambrosetti, A.
    Schiavi, F.
    Opocher, G.
    Paganelli, G.
    [J]. HORMONE AND METABOLIC RESEARCH, 2012, 44 (05) : 411 - 414
  • [5] Peptide Receptor Radionuclide Therapy (PRRT) Using 177Lu-DOTATATE: Early Clinical and Dosimetric Results
    Garkavij, M.
    Nickel, M.
    Sjogreen-Gleisner, K.
    Ljungberg, M.
    Strand, S. E.
    Ohlsson, T.
    Tennvall, J.
    [J]. NEUROENDOCRINOLOGY, 2009, 90 (01) : 113 - 113
  • [6] Peptide receptor radionuclide therapy (PRRT) using 177Lu-Dotatate:: Early clinical and dosimetric results
    Garkavij, M.
    Sjogreen-Gleisner, K.
    Nickel, M.
    Ohlsson, T.
    Wingardh, K.
    Tennvall, J.
    [J]. CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2008, 23 (04) : 524 - 525
  • [7] SPECT/CT calibration using clinical dosimetry workstations for peptide receptor radionuclide therapy (PRRT) in patients treated with 177Lu-DOTATATE
    Mora Ramirez, E.
    Santoro, L.
    Trauchessec, D.
    Chouaf, S.
    Deshayes, E.
    Pouget, J.
    Kotzki, P.
    Bardies, M.
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 : S809 - S810
  • [8] Patient-Specific Dosimetry of 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy with High Activities
    Beykan, S.
    Eberlein, U.
    Werner, R. A.
    Lapa, C.
    Buck, A. K.
    Kudlich, T.
    Lassmann, M.
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2018, 45 : S33 - S33
  • [9] Peptide Receptor Radionuclide Therapy by 177Lu-DOTATATE of a Secreting Cervical Paraganglioma
    Deville, Agathe
    Pinigina, Iuliia
    Al Mansour, Laure
    Abeillon, Juliette
    Tordo, Jeremie
    [J]. CLINICAL NUCLEAR MEDICINE, 2022, 47 (01) : E71 - E73
  • [10] In Vivo Instability of 177Lu-DOTATATE During Peptide Receptor Radionuclide Therapy
    Lubberink, Mark
    Wilking, Helena
    Ost, Amalia
    Ilan, Ezgi
    Sandstrom, Mattias
    Andersson, Camilla
    Fross-Baron, Katarzyna
    Velikyan, Irina
    Sundin, Anders
    [J]. JOURNAL OF NUCLEAR MEDICINE, 2020, 61 (09): : 1337 - 1340
12345